Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5‐year survival of less than 10%. More knowledge of the immune response developed in patients with PDAC is pivotal to develop better combination immune therapies to improve clinical outcome. In this study, we used mass cytometry time‐of‐flight to undertake an in‐depth characterization of PBMCs from patients with PDAC and examine the differences with healthy controls and patients with benign diseases of the biliary system or pancreas. Peripheral blood mononuclear cells from patients with PDAC or benign disease are characterized by the increase of pro‐inflammatory cells, as CD86+ classical monocytes and memory T cells expressing CCR6+ and CXCR3+, associated with T helper 1 (Th1) and Th17 immune responses, respectively. However, PBMCs from patients with PDAC present also an increase of CD39+ regulatory T cells and CCR4+CCR6−CXCR3− memory T cells, suggesting Th2 and regulatory responses. Concluding, our results show PDAC develops a multifaceted immunity, where a proinflammatory component is accompanied by regulatory responses, which could inhibit potential antitumor mechanisms. This study used mass cytometry to undertake an extensive characterization of the circulating immune cells in patients with pancreatic ductal adenocarcinoma (PDAC). We show that PBMCs from patients with PDAC are characterized by the increase of proinflammatory cells, as CD86+ classical monocytes and memory T cells expressing CCR6+ and CXCR3+, associated with T helper 1 (Th1) and Th17 immune responses, respectively. However, PBMCs from patients with PDAC also show an increase of CD39+ regulatory T cells and CCR4+CCR6−CXCR3− memory T cells, suggesting Th2 and regulatory responses.